BioSpace News Archive

Deals

Top 3 Takeover Targets for Pfizer

The year is already off to a good start with mergers and acquisitions in the biopharma industry.

January 23, 2018
·
3 min read
·
Mark Terry
Business

Biotech Startup Formed by 4 Ex-Pfizer Employees Inks Deal With Former Employer

The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders.

January 23, 2018
·
2 min read
·
Alex Keown
Pharm Country

New Kid Tmunity Banks $100M From Gilead and Facebook Billionaire Sean Parker

The funds raised will partly go towards funding two clinical trials that have already opened.

January 23, 2018
·
3 min read
·
Mark Terry
Deals

Gilead’s Kite Pays $135M for Ex-Agensys R&D Building

The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.

January 23, 2018
·
1 min read
Deals

How Juno’s CEO Broke the $9B M&A News to Employees

Employees of Juno received a surprise in their Monday morning emails.

January 23, 2018
·
2 min read
·
Alex Keown
BioCapital

Senate Vote to End Government Shutdown Suspends Medical Device Tax

The first payments would have been due by Jan. 29, 2018.

January 23, 2018
·
1 min read
FDA

FDA OKs Topcon’s Ocular Diagnostic Instrument

Topcon’s touted its system as being able to quickly penetrate ocular tissues without being obscured by hemorrhage or media opacities.

January 23, 2018
·
1 min read
Drug Development

Zealand Pharma to Present Phase II Results on Glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.

The trial was conducted at Rigshospitalet, University of Copenhagen, Denmark, one of the world’s leading centers for the treatment of SBS and top-line results were reported in June 2017

January 23, 2018
·
3 min read
Genetown

Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock

The offering is expected to close on or about January 25, 2018, subject to customary closing conditions.

January 23, 2018
·
5 min read
China Sees Promise, not Danger in Crispr Gene-Editing Trials

China researchers have treated 86 cancer patients with genetically modified versions of their own immune cells.

January 23, 2018
·
1 min read